Chimeric Therapeutics expects a phase-1B clinical trial into its “natural killer” cell therapy for newly-diagnosed patients with acute myeloid leukemia (AML) to be open for new enrolments before the end of the year.
The study, which has received investigational new drug clearance from the United States Food and Drug Administration (FDA), is designed to enrol up to 20 patients who are not…
